Will began his career working at the FDA Office of Orphan Drug Products. While there, he led an internal study to determine why drug candidates for rare disease patients were not approved. A surprisingly large proportion of these drugs were abandoned because of an inability to find patients. After the FDA, Will spent 7 years at Baxter Healthcare, eventually managing all US production of rare disease plasma products, leading a staff of 100 personnel and a budget of $20 million. After reading about the MIT initiative to find “needle-in-a-haystack” targets, he connected with their lab and built WeHealth to address the problem that he observed at the FDA by connecting patients with advocacy groups and clinical research,. Will holds a BS in Biological Sciences from Stanford University and an MBS in Biotech Management from Keck Graduate Institute.

Mahrad's passions are deeply rooted in supporting health equity initiatives to connect underserved patient communities with resources and support. Prior to co-founding WeHealth, Mahrad worked as a management consultant for Eversana, where he partnered with life sciences companies to deliver strategic business solutions and enable broad access to innovative treatments. While there, he noticed the pharmaceutical industry's inability to mobilize digital solutions for discovering and developing treatments, which hindered product launches and patient access to timely treatment. Through WeHealth, Mahrad strives to empower patients with access to resources, treatment and support. Mahrad earned his BS in Biology from Loyola Marymount University in Los Angeles, CA and his MBS in biotech management from Keck Graduate Institute.